Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Smith, Tasanee S T ^a   Nanji, Afshan A ^b   Greenberg, Paul B ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VASCULOTROPIN ANTIBODY;

CATARACT; CENTRAL RETINA VEIN OCCLUSION; CINAHL; CLINICAL TRIAL; COCHRANE LIBRARY; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; EMBASE; ENDOPHTHALMITIS; EYE INFLAMMATION; FLUORESCENCE ANGIOGRAPHY; HUMAN; INFORMATION RETRIEVAL; INTRAOCULAR HYPERTENSION; MEDLINE; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINA TEAR; REVIEW; STEREOPHOTOGRAMMETRY; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 55049129864     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007325     Document Type: Review

References (51)

1. Adamczuk 2002 Adamczuk YP, Iglesias Varela ML, Martinuzzo ME, Cerrato GS, Forastiero RR. Central retinal vein occlusion and thrombophilia risk factors. Blood Coagulation and Fibrinolysis 2002;13(7):623-6.
2. Adamis 1996 Adamis AP, Shima DT, Tolentino MJ, Gragoudas ES, Ferrara N, Folkman J, et al.Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Archives of Ophthalmology 1996;114(1):66-71.
3. Aiello 1995 Aiello LP, Pierce EA, Foley ED, Takagi H, Chen HRL, Ferrara N, et al.Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proceedings of the National Academy of Sciences of the United States of America. 1995;92:10457-61.
4. Bashshur 2004 Bashshur ZF, Ma'luf RN, Allam S, Jurdi FA, Haddad RS, Noureddin BN. Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Archives of Ophthalmology 2004;122(8):1137-40.
5. Boyd 2002 Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, Cree IA, et al.Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Archives of Ophthalmology 2002;120(12):1644-50.
6. Campochiaro 2008 Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, et al.Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Molecular Therapy 2008;16(4):791-9.
7. Catier 2005 Catier A, Tadayoni R, Paques M, Erginay A, Haouchine B, Gaudric A, et al.Characterization of macular edema from various etiologies by optical coherence tomography. American Journal of Ophthalmology 2005;140(2):200-6.
8. Cekic 2005 Cekic O, Chang S, Tseng JJ, Barile GR, Weissman H, Del Priore LV, et al.Intravitreal triamcinolone treatment for macular edema associated with central retinal vein occlusion and hemiretinal vein occlusion. Retina 2005;25(7):846-50.
9. Chang 2007 Chang MA, Fine HF, Bass E, Bressler SB, Schachat AP, Solomon SD, et al.Patients' preferences in choosing therapy for retinal vein occlusions. Retina 2007;27(6):789-97.
10. Costa 2007 Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007;27(2):141-9.
11. CRUISE 2008 CRUISE Study Group. A study of the efficacy and safety of ranibizumab injection in patients with macular edema secondary to central retinal vein occlusion (CRUISE). http: //clinicaltrials.gov/ct2/show/NCT00485836 (accessed 14 May 2008).
12. CVOS Group 1995 CVOS Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995;102(10):1425- 33.
13. Deeks 2008 Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
14. Edelman 2005 Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbitmodel of blood-retinal and blood-aqueous barrier breakdown. Experimental Eye Research 2005;80(2):249-58.
15. Elman 1990 Elman MJ, Bhatt AK, Quinlan PM, Enger C. The risk for systemic vascular diseases and mortality in patients with central retinal vein occlusion. Ophthalmology 1990;97(11):1543-8.
16. Gao 2006 Gao W, Wang YS, Zhang P, Wang HY. Hyperhomocysteinemia and low plasma folate as risk factors for central retinal vein occlusion: a case-control study in a Chinese population. Graefes Archive for Clinical and Experimental Ophthalmology 2006;244(10):1246-9.
17. Glanville 2006 Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
18. Hayreh 2001 Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. American Journal of Ophthalmology 2001;131(1):61-77.
19. Hee 1995 Hee MR, Puliafito CA, Wong C, Duker JS, Reichel E, Rutledge B, et al.Quantitative assessment of macular edema with optical coherence tomography. Archives of Ophthalmology 1995;113(8):1019- 29.
20. Higgins 2008 Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
21. Homsi 2007 Homsi J, Daud AI. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control 2007;14(3):285-94.
22. Ip 2004 Ip MS, Gottlieb JL, Kahana A, Scott IU, Altaweel MM, Blodi BA, et al.Intravitreal triamcinolone for the treatment of macular edema associated with central retinal vein occlusion. Archives of Ophthalmology 2004;122(8):1131-6.
23. Iturralde 2006 Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, et al.Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-termstudy. Retina 2006;26(3):279-84.
24. Kinge 2008 Kinge B, Stordahl P, Forsaa V, Fossen K, Haugstad M, Helgesen O, et al.The Rocc-study: A randomized study comparing the safety and efficacy of ranibizumab (Lucentis) to sham in patients with macular edema secondary to central retinal vein occlusion (CRVO). IOVS 2008; 49: 2701.
25. Klein 2008 Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the beaver dameye study. Archives of Ophthalmology 2008;126(4):513-8.
26. Kourlas 2007 Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: A review. Clinical Therapeutics 2007;29(9):1850-61.
27. Larsson 1999 Larsson J, Hillarp A, Olafsdottir E, Bauer B. Activated protein C resistance and anticoagulant proteins in young adults with central retinal vein occlusion. Acta Ophthalmologica Scandinavica 1999;77(6):634-7.
28. Lattanzio 2006 Lattanzio R, Sampietro F, Ramoni A, Fattorini A, Brancato R, D'Angelo A. Moderate hyperhomocysteinemia and early-onset central retinal vein occlusion. Retina 2006;26(1):65-70.
29. LCRVO Group 2008 Lucentis for Central Retinal Vein Occlusion Study Group. Lucentis for central retinal vein occlusion (CRVO). http: //clinicaltrials.gov/ct2/show/NCT00406796 (accessed 14 May 2008).
30. Lee 2004 Lee WF, Yang CM. Intravitreal triamcinolone injection for macular edema secondary to increased retinal vascular permeability. Journal of the Formosan Medical Association 2004;103(9):692-700.
31. Lin 2007 Lin JM, Chiu YT, Hung PT, Tsai YY. Early treatment of severe cystoid macular edema in central retinal vein occlusion with posterior subtenon triamcinolone acetonide. Retina 2007;27(2):180-9.
32. Los 2007 Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007;12(4):443-50.
33. Mandelcorn 2007 Mandelcorn MS, Mandelcorn E, Guan K, Adatia FA. Surgical macular decompression for macular edema in retinal vein occlusion. Canadian Journal of Ophthalmology 2007;42(1):116-22.
34. Mitchell 1996 Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Archives of Ophthalmology 1996;114(10):1243-7.
35. Mohamed 2007 Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007;114(3):507-19.
36. Moschos 2007 Moschos MM, Brouzas D, Loukianou E, Apostolopoulos M, Moschos M. Intraocular triamcinolone acetonide for macular edema due to CRVO. A multifocal-ERG and OCT study. Documenta Ophthalmologica 2007;114(1):1-7.
37. Nguyen 2006 Nguyen QD, Tatlipinar S, Shah SM, Haller JA, Quinlan E, Sung J, et al.Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. American Journal of Ophthalmology 2006;142(6):961-9.
38. Ozdek 2005 Ozdek SC, Aydin B, Gurelik G, Bahceci U, Hasanreisoglu B. Effects of intravitreal triamcinolone injection on macular edema and visual prognosis in central retinal vein occlusion. International Ophthalmology 2005;26(1-2):27-34.
39. Pai 2007 Pai SA, Shetty R, Vijayan PB, Venkatasubramaniam G, Yadav NK, Shetty BK, et al.Clinical, anatomic, and electrophysiologic evaluation following intravitrea l bevacizumab for macular edema in retinal vein occlusion. American Journal of Ophthalmology 2007;143(3):601-6.
40. Palmowski-Wolfe 2007 Palmowski-Wolfe AM, Denninger E, Geisel J, Pindur G, Ruprecht KW. Antiphospholipid antibodies in ocular arterial and venous occlusive disease. Ophthalmologica 2007;221(1):41-6.
41. Park 2003 Park CH, Jaffe GJ, Fekrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. American Journal of Ophthalmology 2003;136(3):419- 25.
42. Pe'er 1995 Pe'er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Laboratory Investigation 1995;72(6):638-45.
43. Pe'er 1998 Pe'er J, Folberg R, Itin A, Gnessin H, Hemo I, Keshet E. Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology 1998;105(3):412-6.
44. Schaal 2007 Schaal KB, Hoh AE, Scheuerle A, Schutt F, Dithmar S. Bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe 2007;104(4):285-9.
45. Shahsuvaryan 2003 Shahsuvaryan ML, Melkonyan AK. Central retinal vein occlusion risk profile: a case-control study. European Journal of Ophthalmology 2003;13(5):445-52.
46. Shima 1996 Shima DT, Gougos A, Miller JW, Tolentino M, Robinson G, Adamis AP, et al.Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Investigative Ophthalmology and Visual Science 1996;37(7):1334-40.
47. Stahl 2007 Stahl A, Agostini H, Hansen LL, Feltgen N. Bevacizumab in retinal vein occlusion-results of a prospective case series. Graefes Archive for Clinical and Experimental Ophthalmology 2007;245(10): 1429-36.
48. Vine 2000 Vine AK. Hyperhomocysteinemia: a new risk factor for central retinal vein occlusion. Transactions of the American Ophthalmological Society 2000;98:493-503.
49. Vinores 1999 Vinores SA, Derevjanik NL, Ozaki H, Okamoto N, Campochiaro PA. Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. Documenta Ophthalmologica 1999;97(3-4):217-28.
50. Weger 2002 Weger M, Stanger O, Deutschmann H, Temmel W, Renner W, Schmut O, et al.Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Archive for Clinical and Experimental Ophthalmology 2002;240(4):286-90.
51. Wells 2007 Wells JA, Wroblewski JJ, Macugen in CRVO Study Group. Pegaptanib sodium for the treatment of macular edema following central retinal vein occlusion (CRVO): Functional outcomes. IOVS 2007; 48: 1544.